A Phase 2 interventional study of Adalimumab in Rheumatoid Arthritis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 7 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-20.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 68th largest by enrollment, is one of 4 that started in 2012, is one of 9 in phase 2, and was the 46th registered.
3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is below the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
80 studies in Arthritis, Rheumatoid by AbbVie: 5 open now, 6 under way, 1 of them phase 3. Of 71 finished, 54 (76%) have results posted.
Among the 80 studies in Arthritis, Rheumatoid by AbbVie, this one is the 32nd largest by enrollment of the 38 interventional ones that give a count, is one of 8 that started in 2012, is one of 16 in phase 2, and was the 27th registered.
AbbVie’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 80 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
This study will compare injection site pain levels between current Humira® formulation versus a new formulation of Humira in patients with Rheumatoid Arthritis (RA), who are either currently on a stable dose (minimum six consecutive doses) of on-label Humira or biological naïve who will be prescribed on-label Humira as treatment for their Rheumatoid Arthritis. The study is being conducted in three countries, Australia (3 sites), Canada (2 sites), and Germany (2 sites).
61 participants were randomized, and 60 received at least one dose of the study drug. One participant, who was randomized to the New formulation of adalimumab/Current formulation adalimumab arm of the study, discontinued from the study and never received study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe
Biological: Adalimumab
One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe
Biological: Adalimumab
Subcutaneously 40 mg every other week (eow) or every week (ew) (as dosing requires)
Also known as: Humira, ABT-D2E7
Mean Injection Site Pain on a Visual Analogue Scale (VAS)
The primary response variable is participant's immediate pain of injection on a visual analogue scale (VAS) of 0 to 10 (cm), with 0 representing no pain and 10 representing the worst possible pain.
Time frame: Immediately after injection.
Mean Injection Site Pain on a Visual Analogue Scale (VAS)
The secondary response variable is participant's pain of injection on a visual analogue scale (VAS) of 0 to 10 (cm) recorded 15 minutes after the injection.
Time frame: 15 minutes post injection
Percentage of Participants With no Hemorrhage/Petechiae in the Draize Scale
Hemorrhage/petechiae (bleeding/spots of bleeding underneath the skin) was assessed.
Time frame: 10 minutes and 30 minutes after injection
Percentage of Participants With no Erythema in the Draize Scale
Erythema (redness) was assessed.
Time frame: 10 minutes and 30 minutes after injection
Percentage of Participants With no Edema in the Draize Scale
Edema (swelling) was assessed.
Time frame: 10 minutes and 30 minutes after injection
Percentage of Participants With no Pruritus in the Draize Scale
Pruritus (itching) was assessed.
Time frame: 10 minutes and 30 minutes after injection
Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment.
Time frame: Adverse events were collected from the time of study drug administration until 70 days following discontinuation of study drug. Serious adverse events were collected from the time that participant signed the informed consent.
| Milestone | Current Formulation Adalimumab/New Formulation of Adalimumab | New Formulation of Adalimumab/Current Formulation Adalimumab |
|---|---|---|
| Started | 31 | 30 |
| Completed | 31 | 29 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
The primary response variable is participant's immediate pain of injection on a visual analogue scale (VAS) of 0 to 10 (cm), with 0 representing no pain and 10 representing the worst possible pain.
| cm | Current Formulation Adalimumab | New Formulation of Adalimumab |
|---|---|---|
| Mean Injection Site Pain on a Visual Analogue Scale (VAS) | 4.2 ± 2.72 | 0.9 ± 1.44 |
The secondary response variable is participant's pain of injection on a visual analogue scale (VAS) of 0 to 10 (cm) recorded 15 minutes after the injection.
| cm | Current Formulation Adalimumab | New Formulation of Adalimumab |
|---|---|---|
| Mean Injection Site Pain on a Visual Analogue Scale (VAS) | 1.0 ± 1.61 | 0.4 ± 1.08 |
Hemorrhage/petechiae (bleeding/spots of bleeding underneath the skin) was assessed.
| Percentage of Participants | Current Formulation Adalimumab | New Formulation of Adalimumab |
|---|---|---|
| 10 minutes | 80 | 90 |
| 30 minutes | 81.7 | 91.7 |
Erythema (redness) was assessed.
| Percentage of Participants | Current Formulation Adalimumab | New Formulation of Adalimumab |
|---|---|---|
| 10 minutes | 50 | 63.3 |
| 30 minutes | 60 | 75 |
Edema (swelling) was assessed.
| Percentage of Participants | Current Formulation Adalimumab | New Formulation of Adalimumab |
|---|---|---|
| 10 minutes | 90 | 93.3 |
| 30 minutes | 91.7 | 95 |
Pruritus (itching) was assessed.
| Percentage of Participants | Current Formulation Adalimumab | New Formulation of Adalimumab |
|---|---|---|
| 10 minutes | 98.3 | 95 |
| 30 minutes | 96.7 | 96.7 |
An AE was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment.
| participants | Current Formulation Adalimumab | New Formulation of Adalimumab |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 8 | 4 |
Collected over Adverse events were collected from the time of study drug administration until 70 days following discontinuation of study drug. In addition, SAEs were collected from the time the participant signed the study-specific informed consent.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Current Formulation Adalimumab | — | 0/60 (0%) | 8/60 (13.3%) |
| New Formulation of Adalimumab | — | 0/60 (0%) | 4/60 (6.7%) |
| Event | Current Formulation Adalimumab | New Formulation of Adalimumab |
|---|---|---|
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 2/60 | 1/60 |
| URINARY TRACT INFECTIONInfections and infestations | 2/60 | 0/60 |
| CYSTGeneral disorders | 1/60 | 0/60 |
| INJECTION SITE PRURITUSGeneral disorders | 0/60 | 1/60 |
| INJECTION SITE REACTIONGeneral disorders | 0/60 | 1/60 |
| LOWER RESPIRATORY TRACT INFECTIONInfections and infestations | 1/60 | 0/60 |
| RESPIRATORY TRACT INFECTION VIRALInfections and infestations | 1/60 | 0/60 |
| CONTUSIONInjury, poisoning and procedural complications | 1/60 | 0/60 |
| POST-TRAUMATIC PAINInjury, poisoning and procedural complications | 0/60 | 1/60 |
| UPPER LIMB FRACTUREInjury, poisoning and procedural complications | 1/60 | 0/60 |
All analyses were based on the cITT population, which included all subjects who were randomized and completed both periods and received study drug in both periods of the study (N = 60).
| Age, Continuous(years) | Current Formulation Adalimumab/New Formulation of Adalimumab | New Formulation of Adalimumab/Current Formulation Adalimumab | Total |
|---|---|---|---|
| Mean | 58.3 ± 11.56 | 54.4 ± 14.11 | 56.4 ± 12.90 |
| Sex: Female, Male(Participants) | Current Formulation Adalimumab/New Formulation of Adalimumab | New Formulation of Adalimumab/Current Formulation Adalimumab | Total |
|---|---|---|---|
| Female | 24 | 23 | 47 |
| Male | 7 | 6 | 13 |
The record gives a start of Jan 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2014, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
AbbVie (prior sponsor, Abbott) →